CA3238026A1 - Multicyclic compounds - Google Patents
Multicyclic compounds Download PDFInfo
- Publication number
- CA3238026A1 CA3238026A1 CA3238026A CA3238026A CA3238026A1 CA 3238026 A1 CA3238026 A1 CA 3238026A1 CA 3238026 A CA3238026 A CA 3238026A CA 3238026 A CA3238026 A CA 3238026A CA 3238026 A1 CA3238026 A1 CA 3238026A1
- Authority
- CA
- Canada
- Prior art keywords
- co2me
- compound
- acceptable salt
- pharmaceutically acceptable
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/40—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163279094P | 2021-11-13 | 2021-11-13 | |
| US63/279,094 | 2021-11-13 | ||
| US202163282264P | 2021-11-23 | 2021-11-23 | |
| US63/282,264 | 2021-11-23 | ||
| US202263299749P | 2022-01-14 | 2022-01-14 | |
| US63/299,749 | 2022-01-14 | ||
| US202263317980P | 2022-03-09 | 2022-03-09 | |
| US63/317,980 | 2022-03-09 | ||
| US202263321915P | 2022-03-21 | 2022-03-21 | |
| US63/321,915 | 2022-03-21 | ||
| US202263336476P | 2022-04-29 | 2022-04-29 | |
| US63/336,476 | 2022-04-29 | ||
| US202263375050P | 2022-09-08 | 2022-09-08 | |
| US63/375,050 | 2022-09-08 | ||
| PCT/US2022/049719 WO2023086580A2 (en) | 2021-11-13 | 2022-11-11 | Multicyclic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3238026A1 true CA3238026A1 (en) | 2023-05-19 |
Family
ID=86336491
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3238026A Pending CA3238026A1 (en) | 2021-11-13 | 2022-11-11 | Multicyclic compounds |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250100987A1 (https=) |
| EP (1) | EP4429656A4 (https=) |
| JP (1) | JP2024543479A (https=) |
| CA (1) | CA3238026A1 (https=) |
| IL (1) | IL312774A (https=) |
| WO (1) | WO2023086580A2 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024226703A2 (en) * | 2023-04-27 | 2024-10-31 | The Scripps Research Institute | Asymmetric synthesis and diversification of a stabilized salvinorin a scaffold |
| CN118267384B (zh) * | 2024-03-27 | 2024-12-20 | 徐州医科大学 | κ阿片受体激动剂在制备预防和/或治疗颞叶癫痫药物中的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090088466A1 (en) * | 2005-06-17 | 2009-04-02 | University Of Iowa Research Foundation | Opioid receptor ligands |
| US11512075B2 (en) * | 2017-06-14 | 2022-11-29 | The Scripps Research Institute | Synthesis of 20-nor-salvinorin A |
| US20210186927A1 (en) * | 2018-04-13 | 2021-06-24 | Blumentech, S.L. | Combination product for the induction and/or maintenance of general anesthesia |
| US10556889B1 (en) * | 2018-12-19 | 2020-02-11 | Blue Sky Pharmaceuticals, LLC | Salvinorin derivatives |
-
2022
- 2022-11-11 IL IL312774A patent/IL312774A/en unknown
- 2022-11-11 CA CA3238026A patent/CA3238026A1/en active Pending
- 2022-11-11 EP EP22893676.1A patent/EP4429656A4/en active Pending
- 2022-11-11 WO PCT/US2022/049719 patent/WO2023086580A2/en not_active Ceased
- 2022-11-11 US US18/707,895 patent/US20250100987A1/en active Pending
- 2022-11-11 JP JP2024528455A patent/JP2024543479A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023086580A3 (en) | 2023-07-06 |
| JP2024543479A (ja) | 2024-11-21 |
| IL312774A (en) | 2024-07-01 |
| WO2023086580A2 (en) | 2023-05-19 |
| EP4429656A2 (en) | 2024-09-18 |
| US20250100987A1 (en) | 2025-03-27 |
| EP4429656A4 (en) | 2026-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3442971B1 (en) | Estrogen receptor modulators | |
| CA2850987C (en) | Substituted biaryl alkyl amides | |
| RS59534B1 (sr) | Ciklopropilamini kao lsd1 inhibitori | |
| US20110014699A1 (en) | Prostratin analogs, bryostatin analogs, prodrugs, synthetic methods, and methods of use | |
| EP3816163A1 (en) | Cell necrosis inhibitor, preparation method therefor and use thereof | |
| CN106536498A (zh) | 作为hsp90抑制剂和hsp70诱导剂的具有经修饰醚基的联苯酰胺 | |
| CA3238026A1 (en) | Multicyclic compounds | |
| KR20240045222A (ko) | 3,4-메틸렌다이옥시메스암페타민 및 관련 환각제, 그리고 이들의 용도 | |
| JP2021535909A (ja) | 高活性ｓｔｉｎｇタンパク質アゴニスト化合物 | |
| JP6847851B2 (ja) | Ｎｍｄａ受容体のモジュレーターとしてのピリドピリミジノン及びその使用 | |
| RS62515B1 (sr) | Prekursor leka – derivat aminokiselina | |
| CN114149424A (zh) | 用于治疗疾病的杂环化合物 | |
| CN104292125A (zh) | 萘衍生物及其在药物上的应用 | |
| JP2023538638A (ja) | ピラゾールボロン酸化合物、それを含有する医薬組成物、及びそれらの使用 | |
| CN105658634A (zh) | 作为TCR-Nck相互作用的抑制剂的被醇盐取代的色烯衍生物 | |
| ITMI951900A1 (it) | Derivati idroisochinolinici sostituiti | |
| EP4545534A1 (en) | Heterocyclic compound as taar1 ligand agonist | |
| CA3178798A1 (en) | 3-((1h-pyrazol-4-yl)methyl)-6'-(phenyl)-2h-(1,2'-bipyridin)-2-one derivatives and related compounds as gpr139 antagonists for use in a method of treatment of e.g. depression | |
| CN111848572B (zh) | 酰胺类化合物及其制备方法和用途 | |
| EP3506983B1 (en) | Substituted urea-derivatives for the treatment of pain | |
| CN118598822A (zh) | 一类含芳基的胺类化合物、其制备方法和用途 | |
| WO2024124050A1 (en) | Multicyclic compounds | |
| CA3176429A1 (en) | Modulators of hemoglobin | |
| WO2024124043A1 (en) | Multicyclic compounds | |
| EP4514806B1 (en) | Compositions useful for modulating splicing |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W200 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST OR RESPONSE SUBMITTED ONLINE Effective date: 20240814 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241112 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241112 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251107 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251107 |